Additional population-based studies that address manifestation of serious heart disease, especially after long-term use, dosage comparisons, and interactions with preexisting cardiac risk factors are needed to inform psychiatric treatment decisions. Periods of former use had a similar risk between youth with an exposure history to methylphenidate or amphetamine.ĬONCLUSION: Exposure to methylphenidate and amphetamines salts showed similar risk for cardiac ED visits. The US Food and Drug Administration (FDA) has approved 13 formulations of methylphenidate and 10 formulations of amphetamine for the treatment of attention. After adjustment for differences in covariates, the risk for cardiac ED visits was similar among current users of methylphenidate or amphetamines. RESULTS: A total of 456 youth visited the ED for cardiac reasons during 52783 years of follow-up. Risk between current users of methylphenidate versus amphetamine salts and former users of drugs in these categories was compared by using a time-dependent Cox proportional hazard model that adjusted for differences in gender race age year of the index date disability congenital anomalies history of circulatory disease history of hospital admission and use of antidepressants, antipsychotics, and bronchodilators. Whats the biggest difference in ADHD medications Remember when we only had Ritalin, Adderall, and Dexedrine to treat kids with. We defined cardiac events as first emergency department (ED) visit for cardiac disease or symptoms. Each month of follow-up was classified according to stimulant use into current use or former use. The analysis included all beneficiaries who were between 3 and 20 years of age, enrolled between July 1994 and June 2004, had at least 1 physician diagnosis of ADHD and were newly started on methylphenidate or amphetamine salts. METHODS: A retrospective cohort design using claims data from the Florida Medicaid fee-for-service program representing a total of 2131953 children and adolescents was used. This study aimed to compare the risk for cardiac events in users of methylphenidate and amphetamine salts. While Adderall and Ritalin are both fast-acting stimulants, Concerta and Vyvanse are both long-acting stimulants that are released into the body throughout the. OBJECTIVES: Safety concerns about central nervous system stimulants for the treatment of attention-deficit/hyperactivity disorder (ADHD) include adverse cardiac effects.
0 Comments
Leave a Reply. |